Clinical AI for radiology just received a major vote of confidence. Aidoc, the Israeli-American company behind FDA-cleared AI tools for medical imaging, closed a $150 million Series E round led by Goldman Sachs Alternatives. With participation from General Catalyst, SoftBank Investment Advisors, and NVentures (NVIDIA's venture arm), the company has now raised over $500 million in total funding.
Why This Matters for Healthcare AI
The healthcare AI market is crowded with narrow point solutions, each detecting a single condition from a single imaging modality. Aidoc is betting on a different approach: a foundation model that can analyze multiple pathologies from a unified architecture.
Their Clinical AI Reasoning Engine (CARE) represents this shift. CARE1, the first version, already powers their rib fracture triage tool. But the roadmap is more ambitious. In January 2026, Aidoc received FDA clearance for a triage tool that combines 11 new indications with 3 previously cleared ones, all running from a single model. That brings their total FDA clearances to over 30.
The technical architecture matters here. Traditional medical imaging AI requires separate models for each condition, creating integration headaches for hospitals and maintenance burdens for vendors. A foundation model approach, where one architecture handles multiple diagnostic tasks, is more scalable and easier to deploy.
The aiOS Platform: Enterprise Infrastructure for Clinical AI
Beyond the CARE model, Aidoc has built aiOS, an orchestration layer that connects directly into hospital systems. The platform integrates with imaging platforms (PACS) and electronic health records, running multiple algorithms simultaneously on each scan.
This is where the practical value emerges. When a radiologist reviews a CT scan, aiOS can flag urgent findings like pulmonary embolism while also surfacing incidental abnormalities that might otherwise be missed. The system prioritizes cases by clinical urgency, helping radiologists focus attention where it matters most.
The numbers are significant: Aidoc analyzes tens of millions of patient cases annually across nearly 2,000 hospitals worldwide. That scale provides the data flywheel needed to improve foundation model performance over time.
Where the $150M Will Go
Elad Walach, Aidoc's co-founder and CEO, has outlined three priorities for the new capital.
First, regulatory expansion. FDA clearance remains expensive and time-consuming, with each new indication requiring substantial clinical validation. The funding will support additional clearances across CT and X-ray imaging.
Second, foundation model development. The company is targeting "pixel to draft report" capability within two years. This means the AI would not just flag findings but generate initial radiologist reports, a significant leap in clinical workflow automation.
Third, global deployment. While Aidoc is already present in hospitals across multiple countries, the Series E will fund broader international rollout of the aiOS platform.
Implications for the Gulf Region
The Gulf healthcare sector has been investing heavily in AI-enabled diagnostics. Saudi Arabia's Vision 2030 healthcare transformation includes substantial AI adoption targets, and the UAE has positioned itself as a regional hub for health technology.
For practitioners in this region, Aidoc's trajectory illustrates several important trends.
The foundation model approach is gaining traction in specialized domains, not just language. Just as GPT showed the value of pretraining on broad data before task-specific fine-tuning, medical imaging AI is moving toward unified architectures that can be adapted across conditions.
Regulatory clearance remains a critical moat. With 30+ FDA clearances, Aidoc has accumulated regulatory expertise that new entrants will struggle to replicate quickly.
Enterprise integration trumps point solutions. Hospitals are not looking for more standalone AI tools. They want platforms that embed into existing workflows without creating new friction.
Looking Ahead
Goldman Sachs' involvement signals that Aidoc is likely positioning for an IPO. The combination of recurring revenue from hospital deployments, a growing foundation model capability, and extensive regulatory clearances creates a profile that public markets tend to favor.
For AI practitioners watching healthcare, this round reinforces that clinical AI is moving from proof-of-concept to scaled infrastructure. The companies that win will be those that can deliver enterprise-grade platforms while navigating the regulatory complexity that keeps competitors at bay.
The $150 million is substantial, but the real story is what it enables: a foundation model approach to medical imaging that could fundamentally change how radiologists work. That is worth watching closely.